 |
|
Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled Trials
Philippe Autier, MD;
Sara Gandini, PhD
Arch Intern Med. 2007;167(16):1730-1737.
ABSTRACT
Background Ecological and observational studies suggest that low vitamin D status could be associated with higher mortality from life-threatening conditions including cancer, cardiovascular disease, and diabetes mellitus that account for 60% to 70% of total mortality in high-income countries. We examined the risk of dying from any cause in subjects who participated in randomized trials testing the impact of vitamin D supplementation (ergocalciferol [vitamin D2] or cholecalciferol [vitamin D3]) on any health condition.
Methods The literature up to November 2006 was searched without language restriction using the following databases: PubMed, ISI Web of Science (Science Citation Index Expanded), EMBASE, and the Cochrane Library.
Results We identified 18 independent randomized controlled trials, including 57 311 participants. A total of 4777 deaths from any cause occurred during a trial size–adjusted mean of 5.7 years. Daily doses of vitamin D supplements varied from 300 to 2000 IU. The trial size–adjusted mean daily vitamin D dose was 528 IU. In 9 trials, there was a 1.4- to 5.2-fold difference in serum 25-hydroxyvitamin D between the intervention and control groups. The summary relative risk for mortality from any cause was 0.93 (95% confidence interval, 0.87-0.99). There was neither indication for heterogeneity nor indication for publication biases. The summary relative risk did not change according to the addition of calcium supplements in the intervention.
Conclusions Intake of ordinary doses of vitamin D supplements seems to be associated with decreases in total mortality rates. The relationship between baseline vitamin D status, dose of vitamin D supplements, and total mortality rates remains to be investigated. Population-based, placebo-controlled randomized trials with total mortality as the main end point should be organized for confirming these findings.
INTRODUCTION
Ecological studies in North America have suggested that mortality from several potentially life-threatening chronic health conditions such as cancer, cardiovascular diseases, and diabetes mellitus would increase with increasing latitude, that is, with residence increasingly distant from the equator.1-2 Other studies have shown that the survival of patients with cardiovascular disease or with some cancer (eg, lung, colorectal, and breast cancer) was greater if the diagnosis was made during summer as compared with the winter.3-4 Increasing distance from the equator and winter period were equated to decreasing exposure to sunlight, especially to UV-B radiation (280-315 nm) because with increasing latitude, amounts of UV-B radiation reaching the earth surface decrease faster than amounts of UV-A radiation (315-400 nm).5 Also, seasonal variations are more pronounced for UV-B radiation than for the UV-A radiation.5 Because UV-B radiation is necessary for the synthesis of vitamin D in the skin, it has been hypothesized that associations found between latitude or seasonality and mortality from several chronic conditions could be owing to variations in vitamin D status.6-10Some food products may also represent a source of vitamin D, although of highly variable content (eg, fortified foods, oily fish, eggs, and butter). Hence, low vitamin D status could proceed from the conjunction of insufficient intakes (exogenous source) and of insufficient skin synthesis (endogenous source) of vitamin D. Biological findings have reinforced the likelihood of the vitamin D hypothesis. First, vitamin D receptors have been found in various organs, and activation of these receptors by 1 ,25 dihydroxyvitamin D3 (calcitriol), the physiologically active form of vitamin D, induces cell differentiation and inhibits proliferation, invasiveness, angiogenesis, and metastatic potential.11-12 These biological phenomena are typical of cancer genesis and some of them (eg, differentiation and proliferation) are also involved in cardiovascular ischemic diseases. Second, many tissues express the 1-hydroxylase enzyme.11 So, after 25-hydroxylation of vitamin D in the liver, many cell types are able to convert the circulating 25-hydroxyvitamin D into 1,25-dihydroxyvitamin D, and autocrine or paracrine production of 1,25-dihydroxyvitamin D would depend on serum concentration of 25-hydroxyvitamin D.
In industrialized countries, cancer, cardiovascular diseases, and metabolic disorders such as diabetes mellitus account for 60% to 70% of deaths among subjects 50 years or older.13-14 If the associations made between vitamin D and these conditions were consistent, then interventions effectively strengthening vitamin D status should result in reduced total mortality. In this meta-analysis, we examined the risk of dying from any cause in subjects who participated in randomized trials testing the impact of vitamin D supplementation (ergocalciferol [vitamin D2] or cholecalciferol [vitamin D3]) on any health condition.
METHODS
The study design was the quantitative synthesis of randomized controlled trials that could contribute to evaluating the impact of vitamin D supplementation on death from any cause.
INTERVENTION AND OUTCOME
The outcome of this analysis was total mortality;the supplementation evaluated was vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). Calcitriol and other vitamin D analogues have seldom been tested for prevention purposes. The few small trials that used these compounds for fracture prevention reported a total of 20 deaths from all causes and demonstrated their toxic effects, mainly hypercalcemia.15 We did not include trials that evaluated treatment with 1-hydroxyvitamin D3 (alfacalcidol), the physiologically active form of vitamin D (1,25-dihydroxyvitamin D3 [calcitriol]), or other vitamin D analogues in patients with advanced prostate cancer, chronic renal disease, or end-stage renal disease or in patients undergoing renal dialysis.
LITERATURE SEARCH
The search was carried out for clinical trials, and no language or time restrictions were applied. The literature up to November 2006 was searched using the following databases: PubMed, ISI Web of Science (Science Citation Index Expanded), EMBASE, and the Cochrane Library. For intervention, the following keywords or corresponding MeSH terms were used: vitamin D, cholecalciferol, and ergocalciferol. For methods, the following keywords and or corresponding MeSH terms used were randomized controlled trial and placebo. A first general search was done using combinations of keywords for intervention and for method. After that, we made searches using combinations of intervention keywords with the following outcome keywords (and their corresponding MeSH terms): congestive heart failure, coronary heart disease, cardiovascular disease, fracture, bone mineral density, and bone turnover. Mortality was not a helpful keyword because none of the trials with vitamin D supplements, except for 1 trial in the United Kingdom,16 had mortality as an end point.
The search for keywords in the title and in the abstract was done systematically. A manual search was done of references cited in the selected articles and in selected reviews or books. Any abstract or article whose title or summary contained at least 1 intervention keyword and 1 method keyword or 1 intervention keyword and 1 outcome keyword was retrieved and read.
SELECTION OF ARTICLES
For an article to be included in our analysis, it must have met the following criteria:
- To represent the principal published report on a randomized controlled trial evaluating an intervention with vitamin D. The addition of calcium supplements in the intervention group and the absence of a placebo for vitamin D in the control group (ie, an open-label trial) were not exclusion criteria.
- To be independent from other studies to avoid giving double weight to estimates derived from the same trial.
- To have deaths from any cause reported separately for the intervention and the control groups. If in an article the number of all-cause deaths was not reported by treatment group, we tried to contact corresponding authors to obtain the missing information.
- To have subjects randomized to the intervention and control groups on an individual basis. Cluster randomization (eg, a nursing home taken as a randomization unit) was not valid because mortality in a specific cluster could be increased by a health event (eg, an influenza epidemic) affecting this cluster and not the others.
- To have sufficient information to allow adequate estimation of the relative risks (RRs) and 95% confidence intervals (CIs) (ie, crude data or adjusted RRs and standard errors, 95% CIs, or P values) to estimate mortality risk after vitamin D intake vs placebo or control.
DESCRIPTION OF STUDIES RETRIEVED
A total of 992 articles or abstracts were retrieved and checked for relevance in terms of intervention, design, and reporting of mortality data. This process resulted in retrieving a total of 27 articles or abstracts that published information on randomized clinical trials evaluating effects of vitamin D supplementation on any end point and reporting data on deaths. Of these 27 articles, 9 were not included in the meta-analysis for the following reasons: (1) Two articles referred to the same trial.17-18 (2) Three did not report deaths by treatment arm (16 deaths overall) and this information could not be retrieved.19-21 (3) In 2 trials, the intervention consisted of a set of drugs including vitamin D.22-23 (4) Two trials were based on cluster randomization,24-25 and 1 of them did not report deaths by trial groups.25 A trial in England24 randomized 118 homes for elderly people, including 3717 participants with a mean age of 85 years. The intervention was equivalent to a daily dose of 1100 IU of ergocalciferol. (5) A placebo-controlled randomized trial was excluded because it was impossible to relate numbers of reported deaths (about 17 deaths) with numbers of subjects in randomization groups.26
One article27 compared an open-label trial with a subgroup of the placebo-controlled RECORD (Randomised Evaluation of Calcium Or vitamin D) trial.28 We used the data from the open-label trial and not from the subgroup of the RECORD trial to have independent studies. For the open-label trial, we took the numbers of deaths at the end of the follow-up that were mentioned in another report.15 Table 1 summarizes the 18 studies that were used for the meta-analysis.
|
|
|
|
Table 1. Vitamin D Supplements and All-Cause Mortality: Overview of Trials Selected for Meta-analysis
|
|
|
STATISTICAL ANALYSIS
Denominators used for calculating death rates in each randomization group were all participants randomized to that group (intent-to-treat analysis). Some trials, such as the RECORD trial,28 had a factorial design (eg, calcium and vitamin D supplementation and vitamin D supplementation alone compared with calcium supplementation alone or with placebo). In such cases, in the meta-analyses, data related to groups receiving vitamin D were considered as coming from the "intervention group" and data related to groups not receiving vitamin D were considered as coming from the "control group."
In most of the selected studies, mortality was a relatively rare event, and we therefore ignored the distinction between the various measures of relative risk (ie, odds ratio, rate ratio, and risk ratio). We transformed the RR estimates and their CIs into log RR, and we calculated the corresponding variance using the formula proposed by Greenland44 in 1987. When estimates were not given, we calculated them from tabular data, and we used the Woolf formula to evaluate the standard error of the log odds ratio.44 Logit estimators were used for a correction of 0.5 in every cell of those tables that contained a zero (Proc Freq with SAS [SAS Windows version 8.02; SAS Institute Inc, Cary, North Carolina; 1999]).
The association between intake of vitamin D supplements and all-cause mortality across selected trials was computed as a summary RR (SRR) with 95% CIs. The SRR was considered statistically significant if the 95% CI did not include 1.0.
We assessed the homogeneity of the effect across studies using the large sample test based on the  2 statistic. Since the 2 test has limited power, we considered that statistically significant heterogeneity existed when the P value was  .10.45 Subgroup analyses and meta-regressions were carried out to investigate between-study heterogeneity focusing on type of study, type of control, length of follow-up, vitamin D dose, use of calcium, year of publication, and country. Heterogeneity was compared among subgroup analyses by using the I2 parameter, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than to chance.46 The SRR was estimated pooling the study-specific estimates by random effects models fitted using SAS (Proc Mixed) with maximum likelihood estimate. Two funnel plot–based approaches were used for assessing publication bias: the sensitivity analysis of Copas and Shi47 and the funnel plot regression of ln(RR) on the sample size, weighted by the inverse of the pooled variance.48
RESULTS
The main meta-analysis was carried out on 18 independent randomized controlled trials with individual randomization (Table 1): 12 placebo-controlled and 6 open-label trials. The numbers of trial participants varied from 55 to 36 282. Mean follow-up varied between 6 months to 7 years, with a mean of 5.7 years after adjustment for trial sizes.
The mean daily dose of vitamin D supplements varied from 300 IU18 to 2000 IU,41 but most of the daily doses were between 400 IU and 833 IU. When taking trial sizes into account, the mean daily vitamin D dose was 528 IU. Table 2 indicates a substantial increase from baseline levels of serum 25-hydroxyvitamin D levels in intervention groups, while levels tended to decrease in control groups, translating to a 1.4- to 5.2-fold difference in serum 25-hydroxyvitamin D level between intervention and control groups. However, increases from baseline levels and in-study differences between intervention and control groups seemed unrelated to daily dose taken. Compliance with taking vitamin D supplements in the largest trials (see "Trials With Decent Statistical Power" in the Figure) was 48% in the RECORD Trial,28 59% in the Women's Health Initiative trial,42-43 63% in the trial by Porthouse et al,39 68% in the trial by Ficker et al,40 79% in the trial by Meyer et al,34 80% in the trial by Trivedi et al,16 83% in the trial by Chapuy et al33 in 2002, 85% in the trial by Lips et al,30 and 95% in the trial by Chapuy et al29 in 1992.
|
|
|
|
Table 2. Serum Levels of 25-Hydroxyvitamin D in Randomized Trials With Vitamin D Supplementsa
|
|
|
|
|
|
|
Figure. Meta-analysis of data on all-cause mortality in 18 randomized controlled trials with vitamin D. SRR indicates summary relative risk.
|
|
|
The 18 trials included 57 311 participants, and 4777 deaths for any cause occurred during follow-up. The Figure shows for each selected trial the RRs of dying from any cause associated with taking vitamin D supplements. The SRR synthesizing results of the 18 trials indicated a significant decrease in the risk of all-cause mortality with using vitamin D supplements (SRR, 0.93; 95% CI, 0.87-0.99). There was no indication for heterogeneity (P = .52) or of publication bias (P = .37 with the method of Copas and Shi47 and P = .77 with the method of Macaskill et al48).
A subgroup analysis (Table 3) shows no appreciable change in SRR according to trial duration and dose of vitamin D supplements.Calcium supplements seemed not to be involved in the total mortality decrease, as the SRRs remained similar in trials with or without calcium supplements as part of the intervention. Exclusion of the quasirandomized trial34 did not affect results. Inclusion of 1 cluster-randomized trial25 increased the SRR but also brought substantial heterogeneity. In this respect, exclusion of this trial was justified.
|
|
|
|
Table 3. Vitamin D Supplements and All-Cause Mortality: Subgroup and Sensitivity Analysis
|
|
|
COMMENT
Results of this meta-analysis of randomized controlled trials suggest that intake of vitamin D supplements may decrease total mortality during trial duration. Publication bias toward concealment of trial results showing no impact of vitamin D supplements on all-cause mortality is not likely because total mortality did not constitute a main end point for any of the 18 trials included in the meta-analysis except 1.16 Timing of deaths during trials was never reported, and we thus could not assess whether exclusion of deaths occurring during the first year of follow-up would have modified the SRRs.
The effect on mortality was not likely to be due to calcium supplements, since the 5 trials that did not include calcium supplements in the intervention group16, 29, 34-35,40 had an SRR similar to those found with trials that included both vitamin D and calcium supplements. No relationship was found with dose of vitamin D supplements, but in most trials, the daily dose range was relatively narrow (ie, 400-830 IU), and large variations in size of trials and in compliance to interventions preclude any conclusion on optimal vitamin D daily dose associated with mortality reduction.
Most trials included in the meta-analysis were conducted in frail elderly people who are at high risk of fall or of low-energy fracture, who often have low serum 25-hydroxyvitamin D levels. Vitamin D is known to increase postural stability and to reduce fall incidence by 22% in elderly subjects, but about 15 elderly people must take vitamin D supplements for avoiding 1 person from falling.49 Such an effect cannot translate to a 7% decrease in total mortality. Also, the Women's Health Initiative,42-43 which accounted for nearly half of the participants considered in this meta-analysis, included younger women with a low probability to die because of falls.
Vitamin D regimens used in trials ranged from 300 to 833 IU, and most vitamin D supplements publicly available include a daily dose of 400 IU to 600 IU that entailed no toxic effects. Serum concentration of 25-hydroxyvitamin D is considered as a good reflection of skin synthesis and food intakes of vitamin D.50 Data from 9 trials showed that the intake of vitamin D supplements resulted in increases in serum 25-hydoxyvitamin D levels. Such data were not available for the other trials, including the Women's Health Initiative.42-43 It was thus not possible to assess from this meta-analysis whether a correlation exists between the magnitude of mortality reduction and the difference in circulating 25-hydroxyvitamin D.
Of the 18 randomized trials, 2 included in this meta-analysis (a trial in the United Kingdom16 and the Women's Health Initiative43) reported the association of vitamin D supplements with incidence and mortality of some cancers and of cardiovascular diseases. In the United Kingdom trial, the rate ratios (95% CIs) between the intervention and control groups for the incidence of cardiovascular diseases, cancers, and colorectal cancer were 0.90 (0.77-1.06), 1.11 (0.86-1.42), and 1.02 (0.60-1.74), respectively.16 For mortality, these ratios were 0.84 (0.65-1.10), 0.86 (0.61-1.20), and 0.62 (0.24-1.60), respectively. In the Women's Health Initiative trial, rate ratios (95% CIs) for incidence of cancer and of colorectal cancer were 0.98 (0.91-1.05) and 1.08 (0.86-1.34), respectively, and rate ratios (95% CIs) for mortality were 0.89 (0.77-1.03) and 0.82 (0.52-1.29), respectively.43 Hence, although none of these results reached statistical significance, incidence rate ratios were always close to 1.0, while mortality rate ratios were always lower, suggesting that vitamin D supplementation would affect mortality associated with cancers and cardiovascular diseases, but would probably have less of an effect (or not at all) on their incidence. This hypothesis is reinforced by recent observations: one prospective cohort study among adult Finish male smokers showed an increasing incidence of pancreas cancer with increasing serum 25-hydroxyvitamin D level.51 In contrast, another prospective study showed that women diagnosed as having advanced breast cancer had lower serum 25-hydroxyvitamin D concentrations than women diagnosed as having less advanced breast cancer.52 In a prospective study in which serum 25-hydoxyvitamin D concentration was estimated using an indirect method based on questions, the influence of decreasing concentrations was more manifest for cancer mortality than for cancer incidence.53
A meta-analysis of randomized trials on supplementation with beta carotene, vitamins A and E, ascorbic acid, and selenium found an increased RR for all-cause mortality of 1.06 (95% CI, 1.02-1.10) associated with the taking of these supplements.54 A randomized controlled trial of the Women's Health Study found no effect of supplementation with 600 IU/d of vitamin E on total mortality.55 These results are contrasting with the results from our meta-analysis on vitamin D supplements. Our results also provide reassurance that at ordinary doses, long-term vitamin D supplementation does not seem to be associated with an overall adverse effect.
Mechanisms by which vitamin D supplementation would decrease all-cause mortality are not clear. The physiologically active form of vitamin D (1,25 dihydroxyvitamin D [calcitriol]) acts as a hormone that has pleiotropic skeletal and extra skeletal effects on, among other things, calcium homeostasis, bone formation, cellular proliferation and differentiation, immune system, bile acid transport, rennin production, the endothelium and vascular walls, and the endocrine system.11, 56 Some effects mediated through the activation of the vitamin D receptor, such as inhibition of cellular proliferation and activation of cellular differentiation,12, 57 could reduce aggressiveness of cancerous processes and expansion of atheromatous lesions. Interestingly, the ability of strong cholesterol reducers, the statins, to decrease all-cause mortality could partly be due to increases in vitamin D levels they would provoke or though acting as vitamin D analogues on vitamin D receptors.10, 58 The biological mechanism by which vitamin D would prevent and possibly reduce the severity of type 2 diabetes mellitus59 remains unknown.60
In conclusion, the intake of ordinary doses of vitamin D supplements seems to be associated with decreases in total mortality rates. The relationship between baseline vitamin D status, dose of vitamin D supplements, and total mortality rates remains to be investigated. Population-based, placebo-controlled randomized trials in people 50 years or older for at least 6 years with total mortality as the main end point should be organized to confirm these findings.
AUTHOR INFORMATION
Correspondence: Philippe Autier, MD, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69372 Lyon CEDEX 08, France (autierp{at}iarc.fr).
Accepted for Publication: April 18, 2007.
Author Contributions: Drs Autier and Gandini had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Autier. Acquisition of data: Autier and Gandini. Analysis and interpretation of data: Autier and Gandini. Drafting of the manuscript: Autier. Statistical analysis: Gandini. Administrative, technical, and material support: Autier. Study supervision: Autier.
Financial Disclosure: None reported.
Additional Contributions: The librarians William Russel-Edu of the European Institute of Oncology and Sharon Grant from the International Agency for Research on Cancer retrieved the literature. John Daniels of the International Agency for Research on Cancer provided editorial help.
This article was corrected for typographical errors on 9/17/2007.
Author Affiliations: International Agency for Research on Cancer, Lyon, France (Dr Autier); and the European Institute of Oncology, Milano, Italy (Dr Gandini).
REFERENCES
1. Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003;164:371-377.
PUBMED
2. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D into perspective. Br J Nutr. 2005;94(4):483-492.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
3. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol. 1981;10(4):337-341.
FREE FULL TEXT
4. Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer. 2006;119(7):1530-1536.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
5. IARC. Solar and Ultraviolet Radiation. Vol 55. Lyon, France: International Agency for Research on Cancer; 1992. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.6. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (Unites States). Cancer Causes Control. 2005;16(2):83-95.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
7. Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. 2006;92(1):132-139.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
8. Garland CF, Garland FC, Gorham ED; et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96(2):252-261.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
9. Poole KE, Loveridge N, Barker PJ; et al. Reduced vitamin D in acute stroke. Stroke. 2006;37(1):243-245.
FREE FULL TEXT
10. Grimes DS. Are statins analogues of vitamin D? Lancet. 2006;368(9529):83-86.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
11. Ordonez-Moran P, Larriba MJ, Pendas-Franco N; et al. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci. 2005;10:2723-2749.
WEB OF SCIENCE
| PUBMED
12. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. Mol Cell Biochem. 2003;253(1-2):247-254.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
13. National Center for Health Statistics. Health, United States, 2006, With Chart Book on Trends in the Health of Americans. Hyattsville, MD; National Center for Health Statistics: 2006.14. Niederlaender E. Causes of Death in the EU. Luxembourg City, Luxembourg: Eurostat; October 2006. Population and Social Conditions—Statistics in Focus 10/2006.15. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005(3):CD000227.
PUBMED
16. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ. 2003;326(7387):469-472.
FREE FULL TEXT
17. Komulainen MH, Kroger H, Tuppurainen MT; et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas. 1998;31(1):45-54.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Komulainen M, Kroger H, Tuppurainen MT; et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. J Clin Endocrinol Metab. 1999;84(2):546-552.
FREE FULL TEXT
19. Bischoff HA, Stahelin HB, Dick W; et al. Effects of vitamin d and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003;18(2):343-351.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
20. Graafmans WC, Ooms ME, Hofstee HM, Bezemer PD, Bouter LM, Lips P. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol. 1996;143(11):1129-1136.
FREE FULL TEXT
21. Keane EM, Healy M, O'Moore R, Coakley D, Walsh JB. Vitamin D–fortified liquid milk: benefits for the elderly community-based population. Calcif Tissue Int. 1998;62(4):300-302.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
22. Hedström M, Sjoberg K, Brosjo E, Astrom K, Sjoberg H, Dalen N. Positive effects of anabolic steroids, vitamin D and calcium on muscle mass, bone mineral density and clinical function after a hip fracture: a randomised study of 63 women. J Bone Joint Surg Br. 2002;84(4):497-503.
FULL TEXT
| PUBMED
23. Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005;165(15):1737-1742.
FREE FULL TEXT
24. Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age Ageing. 2006;35(5):482-486.
FREE FULL TEXT
25. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370-378.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
26. Corless D, Dawson E, Fraser F; et al. Do vitamin D supplements improve the physical capabilities of elderly hospital patients. Age Ageing. 1985;14(2):76-84.
FREE FULL TEXT
27. Avenell A, Grant AM, McGee M, McPherson G, Campbell MK, McGee MA, RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention—a randomized controlled trial comparison with a blinded, placebo-controlled design. Clin Trials. 2004;1(6):490-498.
FREE FULL TEXT
28. Grant AM, Avenell A, Campbell MK; et al, RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people: a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621-1628.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
29. Chapuy MC, Arlot ME, Duboeuf F; et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327(23):1637-1642.
WEB OF SCIENCE
| PUBMED
30. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med. 1996;124(4):400-406.
FREE FULL TEXT
31. Baeksgaard L, Andersen KP, Hylstrup L. Calcium and vitamin supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int. 1998;8(3):255-260.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Krieg MA, Jacquet AF, Bremgartner M, Cuttelod S, Thiebaud D, Burckhardt P. Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. Osteoporos Int. 1999;9(6):483-488.
WEB OF SCIENCE
| PUBMED
33. Chapuy MC, Pamphile R, Paris E; et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II Study. Osteoporos Int. 2002;13(3):257-264.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
34. Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI. Can vitamin D supplementation reduce the risk of fracture in the elderly? a randomized controlled trial. J Bone Miner Res. 2002;17(4):709-715.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
35. Latham NK, Anderson CS, Lee A; et al. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects. J Am Geriatr Soc. 2003;51(3):291-299.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Harwood RH, Sahota O, Gaynor K; et al. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NoNOF) Study. Age Ageing. 2004;33(1):45-51.
FREE FULL TEXT
37. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. 2004;19(8):1221-1230.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
38. Brazier M, Grados F, Kamel S; et al. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablets in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2005;27(12):1885-1893.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
39. Porthouse J, Cockayne S, King C; et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ. 2005;330(7498):1003.
FREE FULL TEXT
40. Flicker L, MacInnis R, Stein M; et al. Should all older people in residential care receive vitamin D to prevent falls? results of a randomised trial [abstract]. J Bone Miner Res. 2004;19(suppl 1):S99.
41. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-759.
FREE FULL TEXT
42. Jackson RD, LaCroix AZ, Gass M; et al, Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-683.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
43. Wactawski-Wende J, Kotchen JM, Anderson GL; et al, Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354(7):684-696.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
44. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
WEB OF SCIENCE
| PUBMED
45. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in "meta-epidemiological" research. Stat Med. 2002;21(11):1513-1524.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
46. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
47. Copas JB, Shi JQ. A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res. 2001;10(4):251-265.
FREE FULL TEXT
48. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001;20(4):641-654.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
49. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC; et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291(16):1999-2006.
FREE FULL TEXT
50. Bouillon R, Moody T, Sporn M, Barrett JC, Norman AW. NIH deltanoids meeting on vitamin D and cancer: conclusion and strategic options. J Steroid Biochem Mol Biol. 2005;97(1-2):3-5.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
51. Stolzenberg-Solomon RZ, Vieth R, Azad A; et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006;66(20):10213-10219.
FREE FULL TEXT
52. Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25 hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 2006;59(12):1334-1336.
FREE FULL TEXT
53. Giovannucci E, Liu Y, Rimm EB; et al. A prospective Study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451-459.
FREE FULL TEXT
54. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364(9441):1219-1228.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
55. Lee IM, Cook NR, Gaziano JM; et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65.
FREE FULL TEXT
56. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol. 2006;102(1-5):156-162.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
57. Pendás-Franco N, Gonzalez-Sancho JM, Suarez Y; et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation. 2007;75(3):193-207.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
58. Pérez-Castrillón JL, Vega G, Abad L; et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99(7):903-905.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
59. Pittas AG, Dawson-Hughes B, Li T; et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29(3):650-656.
FREE FULL TEXT
60. Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together—a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses. 2007;68(3):607-619.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Investigating Factors of Decline in Cognitive Function or Dementia—Reply
David J. Llewellyn, Kenneth M. Langa, Iain A. Lang, and David Melzer
Arch Intern Med. 2011;171(3):267.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Can Vitamin D Reduce Total Mortality?
Edward Giovannucci
Arch Intern Med. 2007;167(16):1709-1710.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial)
Avenell et al.
J. Clin. Endocrinol. Metab. 2012;97:614-622.
ABSTRACT
| FULL TEXT
Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies
Zittermann et al.
Am J Clin Nutr 2012;95:91-100.
ABSTRACT
| FULL TEXT
The Scots' Paradox: Can Sun Exposure, or Lack of it, Explain Major Paradoxes in Epidemiology?
GILLIE
Anticancer Res 2012;32:237-248.
ABSTRACT
| FULL TEXT
Vitamin D Status and Mortality of German Hemodialysis Patients
KRAUSE et al.
Anticancer Res 2012;32:391-395.
ABSTRACT
| FULL TEXT
Serum 25-Hydroxyvitamin D and Pulmonary Function in Older Disabled Community-Dwelling Women
Semba et al.
J Gerontol A Biol Sci Med Sci 2011;0:glr213v1-glr213.
ABSTRACT
| FULL TEXT
Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI)
Eaton et al.
Am J Clin Nutr 2011;94:1471-1478.
ABSTRACT
| FULL TEXT
Association of Glucocorticoid Use and Low 25-Hydroxyvitamin D Levels: Results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006
Skversky et al.
J. Clin. Endocrinol. Metab. 2011;96:3838-3845.
ABSTRACT
| FULL TEXT
The pathogenesis, diagnosis, investigation and management of osteoporosis
Sandhu and Hampson
J. Clin. Pathol. 2011;64:1042-1050.
ABSTRACT
| FULL TEXT
Vitamin D status and mortality in chronic kidney disease
Pilz et al.
Nephrol Dial Transplant 2011;26:3603-3609.
ABSTRACT
| FULL TEXT
Vitamin D and Cardiovascular Disease: Will It Live Up to its Hype?
Lavie et al.
J Am Coll Cardiol 2011;58:1547-1556.
ABSTRACT
| FULL TEXT
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set
Bolland et al.
Am J Clin Nutr 2011;94:1144-1149.
ABSTRACT
| FULL TEXT
Vitamin D and Cardiovascular Disease: Time for Large Randomized Trials
Camargo
J Am Coll Cardiol 2011;58:1442-1444.
FULL TEXT
Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study
Ford et al.
Int J Epidemiol 2011;40:998-1005.
ABSTRACT
| FULL TEXT
Diet, Environmental Factors, and Lifestyle Underlie the High Prevalence of Vitamin D Deficiency in Healthy Adults in Scotland, and Supplementation Reduces the Proportion That Are Severely Deficient
Zgaga et al.
J. Nutr. 2011;141:1535-1542.
ABSTRACT
| FULL TEXT
Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Elamin et al.
J. Clin. Endocrinol. Metab. 2011;96:1931-1942.
ABSTRACT
| FULL TEXT
Components of a Cardioprotective Diet: New Insights
Mozaffarian et al.
Circulation 2011;123:2870-2891.
FULL TEXT
Vitamin D and cardiovascular disease: a jack of all trades?
de Boer
Journal of Renin-Angiotensin-Aldosterone System 2011;12:123-124.
Vitamin D and Cardiovascular Disease
Temmerman
J. Am. Coll. Nutr. 2011;30:167-170.
ABSTRACT
| FULL TEXT
Inequities in advice on vitamin D?
Handel et al.
QJM 2011;104:547-549.
FULL TEXT
Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure
Schierbeck et al.
Eur J Heart Fail 2011;13:626-632.
ABSTRACT
| FULL TEXT
Vitamin D status: to be considered in heart failure patients!
Pilz and Tomaschitz
Eur J Heart Fail 2011;13:595-596.
FULL TEXT
Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial
Kumar et al.
BMJ 2011;342:d2975-d2975.
ABSTRACT
| FULL TEXT
Ultraviolet Exposure and Mortality among Women in Sweden
Yang et al.
Cancer Epidemiol. Biomarkers Prev. 2011;20:683-690.
ABSTRACT
| FULL TEXT
Requirements for Vitamin D Across the Life Span
Grant and Boucher
Biol Res Nurs 2011;13:120-133.
ABSTRACT
Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men
Center et al.
J. Clin. Endocrinol. Metab. 2011;96:1006-1014.
ABSTRACT
| FULL TEXT
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study
Drechsler et al.
Nephrol Dial Transplant 2011;26:1024-1032.
ABSTRACT
| FULL TEXT
Seasonal variation of serum vitamin D and the effect of vitamin D supplementation in Irish community-dwelling older people
Romero-Ortuno et al.
Age Ageing 2011;40:168-174.
ABSTRACT
| FULL TEXT
Investigating Factors of Decline in Cognitive Function or Dementia--Reply
Llewellyn et al.
Arch Intern Med 2011;171:267-267.
FULL TEXT
Review Article: Health benefit of increased serum 25(OH)D levels from oral intake and ultraviolet-B irradiance in the Nordic countries
Grant et al.
Scand J Public Health 2011;39:70-78.
ABSTRACT
Mitigating epidemic vitamin D deficiency: The agony of evidence
Bosomworth
cfp 2011;57:16-20.
FULL TEXT
Attenuer la carence epidemique en vitamine D: La tourmente des donnees scientifiques
Bosomworth
cfp 2011;57:e1-e6.
FULL TEXT
Vitamin D and the heart: Why we need large-scale clinical trials
MANSON
Cleveland Clinic Journal of Medicine 2010;77:903-910.
ABSTRACT
| FULL TEXT
Stimulation of Sirt1-Regulated FoxO Protein Function by the Ligand-Bound Vitamin D Receptor
An et al.
Mol. Cell. Biol. 2010;30:4890-4900.
ABSTRACT
| FULL TEXT
Plasma vitamin D and mortality in older men: a community-based prospective cohort study
Michaelsson et al.
Am J Clin Nutr 2010;92:841-848.
ABSTRACT
| FULL TEXT
Serum 25-Hydroxyvitamin D, Parathyroid Hormone, and Mortality in Older Men
Cawthon et al.
J. Clin. Endocrinol. Metab. 2010;95:4625-4634.
ABSTRACT
| FULL TEXT
Effect of a Single Oral Dose of 600,000 IU of Cholecalciferol on Serum Calciotropic Hormones in Young Subjects with Vitamin D Deficiency: A Prospective Intervention Study
Cipriani et al.
J. Clin. Endocrinol. Metab. 2010;95:4771-4777.
ABSTRACT
| FULL TEXT
The vitamin D system: a crosstalk between the heart and kidney
Cozzolino et al.
Eur J Heart Fail 2010;12:1031-1041.
ABSTRACT
| FULL TEXT
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients
Drechsler et al.
Eur Heart J 2010;31:2253-2261.
ABSTRACT
| FULL TEXT
The expanding spectrum of biological actions of vitamin D
Rojas-Rivera et al.
Nephrol Dial Transplant 2010;25:2850-2865.
FULL TEXT
Vitamin D nutritional policy needs a vision for the future
Norman and Bouillon
Exp Biol Med 2010;235:1034-1045.
ABSTRACT
| FULL TEXT
Associations among 25-Hydroxyvitamin D, Diet Quality, and Metabolic Disturbance Differ by Adiposity in Adults in the United States
Beydoun et al.
J. Clin. Endocrinol. Metab. 2010;95:3814-3827.
ABSTRACT
| FULL TEXT
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
Bolland et al.
BMJ 2010;341:c3691-c3691.
ABSTRACT
| FULL TEXT
Vitamin D and Risk of Cognitive Decline in Elderly Persons
Llewellyn et al.
Arch Intern Med 2010;170:1135-1141.
ABSTRACT
| FULL TEXT
Serum 25-Hydroxyvitamin D and Depressive Symptoms in Older Women and Men
Milaneschi et al.
J. Clin. Endocrinol. Metab. 2010;95:3225-3233.
ABSTRACT
| FULL TEXT
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
Amital et al.
Ann Rheum Dis 2010;69:1155-1157.
ABSTRACT
| FULL TEXT
Effect of High-Dosage Cholecalciferol and Extended Physiotherapy on Complications After Hip Fracture: A Randomized Controlled Trial
Bischoff-Ferrari et al.
Arch Intern Med 2010;170:813-820.
ABSTRACT
| FULL TEXT
Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromso study
Hutchinson et al.
Eur J Endocrinol 2010;162:935-942.
ABSTRACT
| FULL TEXT
Vitamin D Supplementation in the Age of Lost Innocence
Guallar et al.
ANN INTERN MED 2010;152:327-329.
FULL TEXT
Vitamin D, Adiposity, and Calcified Atherosclerotic Plaque in African-Americans
Freedman et al.
J. Clin. Endocrinol. Metab. 2010;95:1076-1083.
ABSTRACT
| FULL TEXT
Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study
Jenab et al.
BMJ 2010;340:b5500-b5500.
ABSTRACT
| FULL TEXT
Diagnosis and management of vitamin D deficiency
Pearce and Cheetham
BMJ 2010;340:b5664-b5664.
FULL TEXT
Vitamin D, Race, and Cardiovascular Mortality: Findings From a National US Sample
Fiscella and Franks
Ann Fam Med 2010;8:11-18.
ABSTRACT
| FULL TEXT
Vitamin D insufficiency and health outcomes over 5 y in older women
Bolland et al.
Am J Clin Nutr 2010;91:82-89.
ABSTRACT
| FULL TEXT
Role of Vitamin D in Adults Requiring Nutrition Support
Pittas et al.
JPEN J Parenter Enteral Nutr 2010;34:70-78.
ABSTRACT
| FULL TEXT
Vitamin D: An Evidence-Based Review
Kulie et al.
J Am Board Fam Med 2009;22:698-706.
ABSTRACT
| FULL TEXT
Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?
Thadhani
J. Am. Soc. Nephrol. 2009;20:2285-2290.
FULL TEXT
Vitamin D: A D-Lightful Health Supplement
Mullin et al.
Nutr Clin Pract 2009;24:642-644.
FULL TEXT
Vitamin D Supplements vs Plasma Level--Reply
Golomb
Arch Intern Med 2009;169:1536-1537.
FULL TEXT
The Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities
Diaz et al.
J Am Board Fam Med 2009;22:521-527.
ABSTRACT
| FULL TEXT
Vitamin D Supplementation and Cancer Prevention
Lenz
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:365-368.
ABSTRACT
Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment
Llewellyn et al.
J Geriatr Psychiatry Neurol 2009;22:188-195.
ABSTRACT
Epidemiology of Vitamin D Insufficiency and Cancer Mortality
PILZ et al.
Anticancer Res 2009;29:3699-3704.
ABSTRACT
| FULL TEXT
25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification
de Boer et al.
J. Am. Soc. Nephrol. 2009;20:1805-1812.
ABSTRACT
| FULL TEXT
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk
Raimondi et al.
Carcinogenesis 2009;30:1170-1180.
ABSTRACT
| FULL TEXT
Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease
Barreto et al.
CJASN 2009;4:1128-1135.
ABSTRACT
| FULL TEXT
Circulating Calcitriol Concentrations and Total Mortality
Zittermann et al.
Clin. Chem. 2009;55:1163-1170.
ABSTRACT
| FULL TEXT
Reply
O'Keefe et al.
J Am Coll Cardiol 2009;53:2012-2013.
FULL TEXT
Vitamin D in Cancer Patients: Above All, Do No Harm
Goodwin
JCO 2009;27:2117-2119.
FULL TEXT
Food synergy: an operational concept for understanding nutrition
Jacobs et al.
Am J Clin Nutr 2009;89:1543S-1548S.
ABSTRACT
| FULL TEXT
Calcium Plus Vitamin D Supplementation and Mortality in Postmenopausal Women: The Women's Health Initiative Calcium-Vitamin D Randomized Controlled Trial
LaCroix et al.
J Gerontol A Biol Sci Med Sci 2009;64A:559-567.
ABSTRACT
| FULL TEXT
MrOs Is D-ficient
Holick
J. Clin. Endocrinol. Metab. 2009;94:1092-1093.
FULL TEXT
Micronutrients and Older Adults
Marian and Sacks
Nutr Clin Pract 2009;24:179-195.
ABSTRACT
| FULL TEXT
Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988-2004
Ginde et al.
Arch Intern Med 2009;169:626-632.
ABSTRACT
| FULL TEXT
Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data
Vervloet and Twisk
Nephrol Dial Transplant 2009;24:703-706.
ABSTRACT
| FULL TEXT
A Ray of Sunshine for the Vitamin D-Heart Hypothesis
Golomb et al.
Arch Intern Med 2009;169:416-417.
FULL TEXT
Expanding Roles of Vitamin D
Giovannucci
J. Clin. Endocrinol. Metab. 2009;94:418-420.
FULL TEXT
25-Hydroxyvitamin D and Risk of Stroke: Possible Mediation by Statin Therapy?
Lee and Greenfield
Stroke 2009;40:e35-e35.
FULL TEXT
Vitamin D Deficiency: An Important, Common, and Easily Treatable Cardiovascular Risk Factor?
Lee et al.
J Am Coll Cardiol 2008;52:1949-1956.
ABSTRACT
| FULL TEXT
Vitamin D and Diabetes: Let the Sunshine In
Penckofer et al.
The Diabetes Educator 2008;34:939-954.
ABSTRACT
| FULL TEXT
Vitamin D and Hypertension: Does the Women's Health Initiative Solve the Question?
Geleijnse
Hypertension 2008;52:803-804.
FULL TEXT
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon et al.
Endocr Rev 2008;29:726-776.
ABSTRACT
| FULL TEXT
Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography
Pilz et al.
J. Clin. Endocrinol. Metab. 2008;93:3927-3935.
ABSTRACT
| FULL TEXT
Diet, nutrition and cancer: public, media and scientific confusion
Boyle et al.
Ann Oncol 2008;19:1665-1667.
FULL TEXT
The "Sunshine Deficit" and Cardiovascular Disease
Wallis et al.
Circulation 2008;118:1476-1485.
FULL TEXT
Invited Commentary: Physical Activity and Vitamin D
Birrell and Francis
Am J Epidemiol 2008;168:587-589.
ABSTRACT
| FULL TEXT
|
